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ABSTRACT
This dissertation is focused on identifying novel targets of immunomodulatory
(IMiD) drugs. IMiDs are a class of drugs that are used to treat multiple myeloma.
The first chapter is an introduction to the clinical use of IMiDs, as well as the protein
cereblon (CRBN), the primary target of IMiDs. The second chapter describes work
towards the identification of a novel IMiD target, WIZ, that is regulated by CRBN
in an IMiD dependent manner. Mass spectrometry was performed to identify novel
binding partners, and IMiD dependent regulation by CRBN was validated using
chemical and genetic methods. Understanding how these drugs work will inform
the production of more potent and more selective drugs.
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1C h a p t e r 1
INTRODUCTION
1.1 Protein Degradation as a Strategy to Treat Cancer
The proteins inside of the cell are like the metaphorical ship of Theseus: old,
rotting components are constantly being replaced by newer functional ones (Fig. 1.1)
(Bachmair andVarshavsky, 1989). The genetic code acts as the blueprint for how the
ship is to be constructed: what components are to be used, and in what proportions
they are to be combined. Just as a ship constructed from a malfunctioning part, or
the incorrect number of parts, would not function properly, a cell produced with
incorrect proteins or improper number of proteins can result in disease (Reinstein and
Ciechanover, 2006). Therefore, the goal of any therapeutic is to target a component
that is malfunctioning or produced in the wrong quantities.
Figure 1.1: The proteome is like the metaphorical ship of Theseus. Old components
are constantly being replaced by newer ones. Over time, the cell manages to replace
all of its components with newer ones.
One therapeutic strategy is to directly modify the activity of a malfunctioning
component. Small molecules can be used to achieve this, which work by binding
to the target malformed protein and either activate or block the wildtype enzymatic
activity. An example of how a small molecule inhibitor would accomplish this is
the usage of all-trans retinoic acid in the treatment of acute promyelocytic leukemia
(APL) (M. Huang et al., 1988). APL occurs when the retinoic acid receptor (RARA)
undergoes a translocation with the promyelocytic leukemia gene on chromosome
15 to generate a chimeric protein. Normally, retinoic acid receptor is activated by
2retinoic acid to transcribe genes promoting cellular differentiation. However, the
retinoic acid receptor chimera is not responsive to retinoic acid and exerts a dominant
negative effect, causing APL. In healthy individuals, white blood cells help the body
fight off infection and depend on signaling through the retinoic acid receptor to
mature correctly. Because thewhite blood cells inAPLpatients can no longermature
correctly, a large number of immature precursors end up accumulating. Therefore, a
therapeutic regimen would rescue this deficit by restoring proper signaling through
the retinoic acid receptor. Since the chimeric retinoic acid receptor in APL is
responsive to all-trans retinoic acid, all-trans retinoic acid can be used to convert an
improperly made protein into a functional one (M. Huang et al., 1988). All-trans
retinoic acid is effective towards the treatment of acute promyelocytic leukemia
primarily because RARA has a well defined ligand binding site (M. Huang et al.,
1988). Although similar strategies are often effective for targeting enzymes, they
are not effective for diseases caused by defects in other types of proteins, or when
the protein is not produced Cromm and Crews, 2017.
An example of such a disease not treatable by modulating protein function is
Duchenne Muscular Dystrophy, which is caused by a loss of Dystrophin function.
Dystrophin scaffolds the cytoskeleton in muscle fibers, likely making it inaccessible
to small molecule inhibitors (Fairclough, Wood, and Davies, 2013). Additionally,
since Dystrophin in Duchenne Muscular Dystrophy is disrupted by a premature stop
codon, no protein is produced, eliminating the rationale to design a small molecule
modulator to treat the condition (Aartsma-Rus et al., 2009). The result of untreated
Duchenne Muscular Dystrophy is muscle weakness and loss, often manifesting as
death at a young age from cardiac related problems (Eagle et al., 2002). Diseases
like Duchenne Muscular Dystrophy highlight the need for alternative therapeutic
strategies not dependent on protein structure.
One method that has gained prominence in recent years is a genome editing method
called CRISPR, which stand for clustered regularly interspaced palindromic repeats
(Cong et al., 2013). CRISPR is used by prokaryotic organisms to protect them
from attack from viral intruders, but has been repurposed for genome editing in
mammalian cells. The system is comprised of an enzyme (Cas 9), which uses a
cognate RNA to target it to specific sequences of DNA (Mali, Esvelt, and Church,
2013) to cause double strand breaks. These breaks can then be repaired with an
exogenously supplied template via homology directed repair. The exogenously
supplied template can be designed to repair the cleaved DNA sequence, providing a
3mechanism for genomic editing. Since CRISPR modifies DNA, it is not restricted
to enzymes, and therefore can be used more broadly for therapeutics. However, a
limitation of genome-editing methods is it that the length of time it would take to
reach a new equilibrium with the repaired protein depends on the half-life of the
underlying protein. Additionally, the nuclease requires a proteospacer adjacentmotif
(PAM) to be adjacent to the target site in order to bind, which poses a restriction on
the type of proteins that can be repaired based upon their primary sequence (Yilan
Zhang et al., 2014). Finally, actively dividing cells that are easier to transfect are
inherently going to be more amenable to be targeted by this method (Richner and
Krook-Magnuson, 2018). As a result, this method would not be as effective for
difficult to transfect cell types like neurons. Therefore, this illustrates the necessity
of complementary therapeutic strategies.
Additionally, diseases that are caused by producing too many copies of a protein
can be targeted by either adjusting the rate of production or the rate of degradation.
Adjusting the rate of production would have similar limitations as genome editing
based strategies, such as low effectiveness in treating conditions with protein targets
having long half-lives. Additional technical limitations exist, particularly in delivery
of these therapeutics. An example that highlights this limitation is Bevasiranib,
which was developed for the treatment of age-related Macular Degeneration (AMD)
(Garba and Mousa, 2010). As people age, fatty deposits gradually accumulate
underneath the retina, which can cause blindness. This is exacerbated by release
of cytokines like vascular endodermal growth factor (VEGF). Bevasirib is a siRNA
therapeutic. siRNA targets the rate of protein production by catalyzing the decay of
mRNA transcripts before they can be translated into protein. Although Bevasirib
was extremely efficient in removing the mRNA transcripts of VEGF in cell culture
and animal models, the drug was ineffective towards ameliorating the symptoms
of the disease in humans (Reinstein and Ciechanover, 2006; Garba and Mousa,
2010; Shen et al., 2006). Because oligonucleotides are unstable in plasma, macular
degeneration is one of the few diseases that can theoretically be targeted using
siRNA based technology because the eye and skin are some of the few tissues
that can directly uptake the oligonucleotide sequences. Therefore, siRNA based
technologies are extremely restricted in terms of the type of diseases that they
can target, and how effective they are depends on how long it takes to eliminate the
existing copies of the protein. Therefore, it illustrates the practicality of a therapeutic
strategy that works by catalyzing the rate of protein decay.
4Catalyzing the rate of decay is a versatile therapeutic strategy without the limitations
of many of the other tools. Unlike small molecule inhibitors which are primarily
limited to targeting enzymes, drugs that catalyze the rate of decay would be applica-
ble to a larger variety of targets. Since the time to a new equilibrium depends on the
rate of decay, degradation-based methods show promise to work more rapidly than
genome editing or translation based methods (Lai and Crews, 2017). Additionally,
since the cell would have to restore protein levels to reverse the effects of treatment
instead of waiting for a small molecule to dissociate, it would enhance the duration
of the effect. Just as a ship that was constructed from the broken components, or
components that were combined in the wrong proportions, cells undergo disease
states like cancer when too much of a protein, or a bad version of a protein is
produced. Therefore, the goal of a therapeutic strategy would be to identify and
remove a malfunctioning or overproduced component. However, in order for this
strategy to result in a viable therapeutic necessitates understanding the way proteins
are removed from the body, as well as identifying a degradation method that is as
specific and selective as possible.
1.2 Ubiquitin Proteasome System as the Optimal Mechanism to Repurpose
for Drug Design
Just as the way a ship constructed from amalfunctioning component, or components
combined in the wrong proportions, would not be functional, constructing a cell with
amalfunctioning protein or thewrong number of proteins can result in a disease state.
Therefore, one obvious therapeutic strategy would be to remove the component by
redirecting the existing cellularmachinery tomodulate the rate of degradation. Since
there are several ways that a protein can be removed from the body, the objective is
to identify the method that would enable the most precise removal of a protein of
interest. Autophagy is a method of removing proteins, where the cell cannibalizes
itself to liberate biomolecules (Kaur andDebnath, 2015). Unsurprisingly, autophagy
is the most efficient way to convert bulk amounts of organelles or proteins into
individual building blocks (amino acids). Since autophagy is normally triggered
under conditions of extreme stress or starvation, it would be difficult to trigger
autophagy without cannibalizing the entire cell. During autophagy, target proteins
are quarantined from the rest of the proteome by being contained in a double
membrane bound compartment, called the autophagosome (Fig. 1.2a) (Xie and
Klionsky, 2007). The autophagosome can undergo subsequent fusion with the
lysosome, a membrane bound compartment full of hydrolytic enzymes that rapidly
5digests organelles or protein complexes down into simple biomolecules (Fig. 1.2b
and c).
Figure 1.2: Degradation through autophagy. A) Sequestration: Organelles and
complexes are engulfed within a lipid bilayer. B) Fusion: The organelles and
complexes sequestered in a lipid bilayer undergoes subsequent fusion with the
lysosome, a low pH compartment which contains hydrolases. C) Degradation:
This fusion event results in the degradation of materials by hydrolases inside of the
autophagosome.
However, the way that proteins are isolated and eliminated during autophagy make it
a suboptimal pathway to redirect for therapeutic purposes. First, there is no known
way to selectively target certain components for degradation, as it is physically
impossible to selectively enclose one subunit of a protein complex or one part
of an organelle. Similarly, since the engulfed material gets exposed to hydrolytic
enzymes after fusion with the lysosome, there is no way to salvage functional protein
complex members or organelle components. So although autophagy is useful under
starvation conditions where the objective is the convert the existing biomass back
into simple building blocks as efficiently as possible, it is too imprecise and difficult
to control to be useful therapeutically. What is needed is a method of degradation
that selectively exposes a single protein, part of a protein complex, or part of an
organelle to a protease.
Unlike autophagy, where the degradative workhorse is the lysosome, the proteasome
6is multisubunit enzyme that can degrade proteins one by one. The proteasome
is comprised of two subparticles: a 20S core, and two 19S regulatory subunits,
which combine to produce the 26S holoenzyme (Chu-Ping et al., 1994). All of
the proteolytic activity is contained within 7 subunits which make up the two
inner rings of the 20S core (Rubin et al., 1998; J. Lowe et al., 1995). These
subunits can digest proteins by cleaving after basic residues like arginine and lysine
(trypsin-like activity), aromatic/hydrophobic amino acids (chymotrypsin-like), and
acidic residue (caspase-like activity), resulting in peptides that are 4-20 amino acids
long (Goldberg, 2012; Arendt and Hochstrasser, 1997; Wenzel et al., 1994). In
order for something to be digested, it must be inserted into the 20S core of the
proteasome, which is normally blocked off by the N terminal regions of components
of the heptameric α subunit ring (Groll et al., 2000). The protease active sites are
normally sealed within the barrel of the proteasome, which would enable the ability
to selectively degrade a subunit of amulti-protein complex (Tanaka, 2009; Seemuller
et al., 1995). However, substrates cannot be degraded without a mechanism to open
up the proteasome, to allow substrates to interact with the protease active sites.
The 19S particle can gate the 20S pore. The subunits that comprise the hexameric
ring on the bottom of the 19S particle have N terminal tails with a HbYX motif that
can insert into pockets between each monomeric unit of the 20S subunit to allow
it to be opened up (widening the pore from 9 Å to 20 Å) (Rabl et al., 2008). This
allows for the entry of substrates to be degraded. However, since the pore within the
proteasome is 13 Å, which is more narrow than the width of most folded proteins,
meaning that the channel would get clogged if a protein was fed in directly (Lucas
and Ciulli, 2017; Unno et al., 2002; J. Lowe et al., 1995). Therefore, substrates
must be unfolded before being fed into the 20S subunit (Smith et al., 2005; J. Lowe
et al., 1995). The 19S subunit has a heterohexameric ring that is comprised of
AAA ATPases that pull apart proteins before they are fed into the 20S subunit
(Benaroudj and Goldberg, 2000). Nonspecific proteolysis by the proteasome could
have disastrous results. Therefore, what is needed is a mechanism to selectively
target the proteolytic machinery to specific proteins.
The proteasome uses ubiquitin to identify which proteins need to be degraded
(Pickart and Eddins, 2004; Hershko and Heller, 1985). Ubiquitin is an 8 kDa
protein that is ubiquitously expressed in most eukaryotic organisms Goldstein et al.,
1975. TheC terminal glycine on ubiquitin is conjugated to the amine on lysines of the
target proteins via an isopeptide linkage. The proteasome has two 2 receptors, 26S
7Proteasome Regulatory Subunit RPN13 (RPN13) and 26S Proteasome Regulatory
Subunit RPN10 (RPN10) on the 19S particle, that enable it to selectively identify
and enrich for proteins that have been targeted for degradation (Fig. 1.3) (Elsasser
et al., 2004; Verma, Oania, et al., 2004). RPN10 only binds to an ubiquitin if it
is polymerized into a chain with at least 4 monomeric units (Thrower et al., 2000;
Wickliffe et al., 2011). Alternatively, polyubiquitinated proteins can be delivered
to the proteasome via shuttle proteins such as UV Excision Repair Protein Rad23
Homolog A and B (RAD23A and RAD23B) and Ubiquilin-2 (UBQLN2) (Chen
and Madura, 2002; E. D. Lowe et al., 2006). A protein to be degraded must have a
polymer of ubiquitin with at least 4 monomeric units appended to a lysine residue
(Chau et al., 1989). However, since each ubiquitin itself has 7 lysine residues, there
are a minimum of 343 possible sub structures that can be formed. RPN10 is known
to recognize one of the substructures where ubiquitin is polymerized through lysine
48 (Finley et al., 1994; Chau et al., 1989).
Although appending a protein with an ubiquitin polymer creates an affinity tag
the proteasome can use to identify and enrich for proteins that are marked for
degradation, it also could clog the 20S degradative machinery. Therefore, a metallo
enzyme (RPN11) is needed to shear ubiquitin off of the unfolded protein before it
gets fed into the 20S subunit (Verma, Aravind, et al., 2002; Yao and Cohen, 2002).
Although the proteasome is fairly effective at removing proteins that are cytosolic
and soluble, it has problems digesting proteins in other compartments or embedded
in the membrane of an organelle. Therefore, an additional factor, p97/VCP, is
needed to extract the protein so it is accessible to the proteasome (Meyer, Bug, and
Bremer, 2012). p97 has an ATPase domain to provide the energy needed to perform
the extraction (Buchberger et al., 2001). p97 also has a number of adapters that
can divide it into different subcomplexes to further increase the specificity of the
interaction. The function of the proteasome and p97 together enables the removal
of many proteins marked for degradation.
However, both p97 and the proteasome rely upon cellular machinery that only
ubiquitinates proteins that need to be removed. Repurposing both for therapeutic
purposes necessitates being able to selectively ubiquitinate a therapeutic target.
However, it would take an extremely long time for the reaction to occur spontaneously
because the terminal side chain amine on the lysine would need to react with the
carboxylic acid on the C terminus of the ubiquitin to generate an amide bond.
Carboxylic acids make poor leaving groups, meaning that it would be unlikely for
8Figure 1.3: Ubiquitinated proteins are recruited by receptors RPN10 or RPN13 on
the proteasome. The ubiquitin chain is removed en bloc by RPN11, a metallopro-
tease. The protein is unfolded by ATPases and digested into smaller peptides within
the proteasome, by the 20S core peptidases.
the uncatalyzed reaction to occur on a time scale that would be compatible with
life (Stevenson and Williamson, 1958; Hodgman, 1951). Therefore, an enzyme
(ubiquitin-activating enzyme; E1) is needed to convert the carboxylic acid into a
thioester, which is a better leaving group, for the reaction to occur on an appropriate
timescale (Fig. 1.4a). The lysines on the proteins that need to be removed are
chemically indistinguishable from the lysines on the proteins that are to be retained,
meaning that a mechanism is needed to target chemically reactive ubiquitin to the
protein of interest (Fig. 1.4c and d).
A large class of enzymes, E3 ubiquitin ligases, are responsible for targeting acti-
vated ubiquitin to specific proteins (R. Deshaies, 1999). Hundreds of E3 ubiquitin
ligase enzymes tune the specificity of protein degradation by directing the activated
ubiquitin thioester to different subsets of proteins. However, catalysis can only
occur if the activated ubiquitin is oriented towards the target lysine. Therefore,
an enzyme, ubiquitin-conjugating enzyme/E2, positions the activated ubiquitin to
facilitate nucleophilic attack by the lysines on the protein of interest (Fig. 1.4b).
Degrading a protein through the ubiquitin proteasome system instead of through
9Figure 1.4: A) Generation of Ubiquitin Thioester by E1: The C terminal carboxylic
acid is converted into a more reactive thioester by an enzyme called E1. B) Transfer
to E2: For catalysis to occur, the ubiquitin thioester needs to be transferred to a
different enzyme, E2, to orient it correctly. C) Recruitment to HECT domain E3
ubiquitin Ligase: HECT domain E3 ubiquitin ligases target the activated ubiquitin
to the protein of interest. HECT domain ligases work by transferring the ubiquitin
directly onto the E3 before transferring it to the substrate. D)Recruitment to cullin-
RINGDomain E3 ubiquitin ligase: cullin-RINGDomain E3 ubiquitin ligases recruit
the activated ubiquitin to the substrate. They work by positioning the E2 to transfer
the activated ubiquitin directly from the E2 to the substrate. E) Polymerization
of ubiquitin: Since the proteasome can only recognize polymers of ubiquitin with
at least 4 monomeric units, the ligase must create a chain long enough for the
proteasome to grab onto.
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autophagy provides the selectivity necessary to degrade one subunit of a complex
or one protein in an organelle. Since the entire protein or complex is bathed in
hydrolytic enzymes during autophagy, it makes it impossible to selectively remove
a protein that was one component of a complex, or one component of an organelle.
Therefore, a more selective method like the ubiquitin proteasome system is more
suited towards redirecting for therapeutic purposes. Modification of the target
protein with an ubiquitin polymer creates an affinity enrichment handle that the
proteasome can use to identify which proteins need to be degraded. Since E3
ubiquitin ligases are the enzymes that direct activated ubiquitin to specific proteins,
identifying the optimal E3 ubiquitin ligase to target is necessary for redirecting the
proteasome to catalyze the degradation of a therapeutic target.
1.3 Substrate Binding and Catalysis are Decoupled in cullin-RING Type E3
Ubiquitin Ligases
E3 ubiquitin ligases tag substrate proteins with ubiquitin, which serves as an affinity
tag for subsequent enrichment and degradation by the proteasome. Redirecting
the proteasome to digest a therapeutic target necessitates being able to modify the
substrate specificity of an E3 to ubiquitinate a therapeutic target. However, some E3
ubiquitin ligases are more ideal than others to being redirected towards a therapeutic
target. Since the catalytic ubiquitin is directly transferred from the E2 to the E3,
in Homologous to the E6-AP Carboxyl Terminus (HECT) domain type E3 ligases,
it would be more difficult to decouple substrate binding and catalysis (L. Huang
et al., 1999; R. Deshaies, 1999). In contrast, cullin-RING domain type E3 ubiquitin
ligases can have their substrate specificity redirected without antagonizing catalysis
because the catalytic ubiquitin is transferred directly from the E2 to the substrate
(Zheng, Schulman, et al., 2002). Therefore, it is more straightforward to modify
substrate binding without antagonizing catalysis.
The specificity of a cullin-RING type E3 ubiquitin ligase is determined by the sub-
strate receptor, an interchangeable subunit which recruits proteins to the enzymatic
core (Skowyra et al., 1997). Once the target is brought to the enzymatic core, it
is held in proximity to the activated ubiquitin (supplied by the Ub-E2). Both the
substrate receptor and the E2 are fixed to a rigid scaffold (Cullin) to hold them
in place, as well as adapters to facilitate the interaction with the scaffold (Ring
Box protein 1; RBX1 for the E2 and DDB1 or SKP1 are examples of ones for the
substrate receptor) (Fig. 1.5a) (Petroski and R. J. Deshaies, 2005a; Feldman et al.,
1997). Recruiting the target protein to the enzymatic core effectively increases the
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local concentration of ubiquitin from 10-20 μM to 3 mM. However, the complex
is enzymatically inactive because the activated ubiquitin is at least 50 Å from the
target lysine (Fig. 1.5a) (Zheng, Schulman, et al., 2002; Zheng, P.Wang, et al., 2000;
Haas, 1988). Since the ubiquitin polymer is fairly flexible enough, the only thing
that is needed is a way to traverse the 40 Å gap for the complex to be catalytically
competent (Petroski, Kleiger, and R. J. Deshaies, 2006).
Modification of the cullin scaffold with the small ubiquitin-like protein Nedd-8
dislodges RBX1, the adapter for the E2, from the scaffold in a way that allows
the activated ubiquitin to spring across the 50 Å gap (Fig. 1.5b). Once RBX1 is
dislodged from the cullin scaffold, the activated ubiquitin would be able to traverse
the 50Å gap, and the complex has enough flexibility to polymerize ubiquitin through
the distal end (Duda et al., 2008). However, each E2 only brings in 1 equivalents
of activated ubiquitin (Fig. 1.5e). Therefore, a mechanism is needed to regenerate a
complex with a charged E2 so ubiquitin can be polymerized into a chain long enough
for the proteasome to grab onto. For the E3 ligase complex to be regenerated on
a time scale that is compatible with life, the depleted E2 must dissociate rapidly
enough so that the E3 ligase can reassemble with an ubiquitin-charged E2.
Figure 1.5: A) Catalytically inactive cullin-RING Ligase: Cullin-RING ligases are
made up of a substrate receptor that brings in the target protein, the E2 which
brings in the activated ubiquitin, and a rigid scaffold (cullin) which holds the
two together. Both are anchored to the scaffold via adapters. The complex is
normally enzymatically inactive because there is 50 Å between the target protein
and the activated ubiquitin. B) Catalytically active cullin-RING ubiquitin ligase:
Modification of the cullin scaffold with Nedd-8 dislodges RBX1, the adapter for the
E2, to bridge the 50 Å gap.
Previous work on CDC34, the yeast ortholog of the E2 of cullin-RING type E3
12
ubiquitin ligases, showed that although the E2 binds tightly to the E3, the complex
forms and falls apart quickly enough to enable rapid regeneration of the E3 ubiquitin
ligase complex with activated ubiquitin, enabling chain elongation to occur on a time
scale amenable to responding to rapid environmental changes (Kleiger et al., 2009).
However, just because ubiquitin can be polymerized on the appropriate time scale
does not mean it would be constructed with the linkage that enables recognition
by the proteasome, as each ubiquitin has seven lysines. Since proteasome can
recognize substructures where ubiquitin is polymerized through lysine 48 or lysine
63, a mechanism is needed to ensure that ubiquitin is polymerized into one of those
substructures (Saeki et al., 2009; Jacobson et al., 2009; Petroski and R. J. Deshaies,
2005b).
Because the ubiquitin is transferred directly from the E2 to the target substrate in
cullin-RINGE3 ligases, the E2 selects one out of the seven lysines on the ubiquitin to
polymerize (Petroski and R. J. Deshaies, 2005b). The E2 sterically restricts access to
ubiquitin so that lysine 48 has the most access. However, even if the target substrate
is recruited to the substrate receptor, it would only be productive if the cognate
substrate receptor is assembled with the enzymatic core. This presents a problem as
multiple substrate receptors can combine with the enzymatic core. Most substrate
receptors are not assembled with the enzymatic core (Reitsma et al., 2017). Without
a mechanism to adjust the relative stoichiometry of substrate receptors assembled
with the enzymatic core, there would be no way to adjust to a sudden fluctuation
in the amount of substrate. One solution is to recycle the enzymatic core from
complexes that are enzymatically inactive, or not bound to substrate. However, it
takes half a week for the substrate receptor to dissociate from the enzymatic core,
which is far too slow to readjust the relative stoichiometry of different substrate
receptors assembled with the enzymatic core on a time scale compatible with life
(Pierce et al., 2013). Therefore, a mechanism is needed to accelerate the rate of
dissociation of the substrate receptor so the enzymatic core can be recycled from
inactive complexes.
Cullin-associated and neddylation-dissociated protein 1 (Cand1) accelerates the
disassembly of complexes that are enzymatically inactive, or where the enzymatic
core does not have the Nedd-8 modification (Pierce et al., 2013). As a result, the
enzymatic core can rapidly reassemble with a different set of substrate receptors to
accommodate a sudden shift in relative occupancy of substrate receptors. However,
because none of the core enzymes recycled by Cand1 are modified with Nedd-8,
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the complexes that would reform would be enzymatically inactive and vulnerable
to disassembly by Cand1 before the substrate can be ubiquitinated. Previous work
demonstrated that the complex is neddylated as the new complex is formed (X. Liu
et al., 2018). CSN, the enzyme complex that cleaves the Nedd-8 modification, only
works on proteins that are not in active complex with substrate (Fig. 1.6) (Mosadeghi
et al., 2016). As a result,the relative stoichiometry of substrate receptors assembled
with the enzymatic core can rapidly adjust to dynamic changes in relative occupancy
of different substrate receptors.
1.4 CRBN as an Ideal Substrate Receptor to Design a Proteolysis Targeting
Chimera
Cullin-RING E3 ligases are comprised of an enzymatic core made up of a rigid
scaffold bound to an E2 that brandishes the chemically activated ubiquitin, and an
interchangeable substrate receptor to direct the enzyme to subsets of proteins (R.
Deshaies, 1999). Since the substrate binding and catalytic activity are uncoupled,
it makes it the ideal type of E3 ubiquitin ligase to redirect towards degrading a
therapeutic target. Redirecting a cullin-RING E3 ligase to ubiquitinate a therapeutic
target can be accomplished by scaffolding the interaction between the substrate
receptor and a novel protein with a small molecule. However, substrate receptors
tend to have exposed extended surface that are well suited to mediating protein-
protein interactions, but nightmarish from the perspective of small molecule design
(Lucas and Ciulli, 2017).
The preferred motif is a small well defined hydrophobic pocket that would place
therapeutic target in proximity to the charged E2. Therefore, it is unsurprising that
all of the substrate receptors that have been successfully redirected to target different
proteins have a small hydrophobic pocket that mediates the recognition of an amino
acid sequence, or degron with a modified amino acid. An example of such a
substrate receptor is Von Hippel Lindau (VHL), which normally binds to a hydroxyl
proline in a process that regulates HIF-1α, a transcription factor that is responsive
to molecular oxygen (Min et al., 2002). HIF-1α is hydroxylated in the presence
of oxygen, which enables VHL to bind and ubiquitinate it (L. E. Huang and Bunn,
2003). VHL can distinguish between the hydroxylated form because of 2 hydrogen
bonding interactions provided by a buried histidine that provide 1000-fold selectivity
(Min et al., 2002; Hon et al., 2002). The hydroxylated peptide binds through an
extended conformation on the surface of the protein, with the hydroxylated proline
wedged into a gap. Therefore, it would be the type of binding that would be difficult
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Figure 1.6: The cullin-RING Ligase cycle. A) Substrate Recruitment: Substrate
receptors recruit the substrate to the enzymatic core. B) Conversion to Catalyt-
ically Active form: UBC12 neddylates the cullin scaffold, converting it into an
enzymatically active form. C) Ubiquitination of Substrate: E3 ubiquitin ligase
complex ubiquitinates substrate, earmarking it for degradation. D) Conversion into
catalytically inactive form by CSN: CSN deneddylates the cullin scaffold, making
the complex enzymatically inactive. C) Recycling the enzymatic core by Cand1:
Cand1 binds to the enzymatically inactive core, and catalyzes the rate of dissocia-
tion of the substrate receptor, allowing the enzymatic core to combine with a new
substrate receptor.
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to replicate with a small molecule because it’s mostly exposed, although the kinetics
would enable the fast assembly and disassembly of the E3-substrate complex.
Similarly, cereblon (CRBN) is also a substrate receptor that contains a small well
defined binding pocket. CRBN is one of the substrate receptors associated with an
E3 ligase with an enzymatic core that is comprised of DDB1 (the substrate receptor
adapter) and Cullin4a. Substrate receptors that assemble with the enzymatic core
are referred to as DDB1 Cul4 Associated Factors (DCAFs) (Petzold, Fischer, and
Thomä, 2016). Most DCAFs have a WD40 domain to facilitate protein-protein
interactions that form a large extended surfaces. Instead, CRBN is comprised
of a seven α helical bundle, an N terminal region with homology to a bacterial
Lon protease, and a C terminus with a similar fold to pseudouridine synthetase or
bacterial methionine sulfoxide reductase (Chamberlain et al., 2014; Petzold, Fischer,
and Thomä, 2016). CRBN is anchored to DDB1, the adapter for Cul4a by the seven
α helical bundle, which inserts between the two propellers that are produced by the
WD40 domain (BPA, BPC) (Fig. 1.7).
The pseuduridine synthase/bacterial methionine sulfoxide reductase like domain in
CRBN faces where the charged ubiquitin-E2 is, and is believed to be the substrate
binding domain. Like VHL, CRBN has a well-defined hydrophobic pocket formed
by three different tryptophans that is directly facing where the ubiquitinated E2
would be. Additionally, crystallographic studies indicated that there is a zone where
a potential substrate could be ubiquitinated because the scaffold could rotate 150◦.
The hydrophobic binding domain has structural similarity to a domain known to
recognize acetylated and methylated lysines.
The domain was shown to mediate the recognition of a substrate with an acetyl
degron, and was also shown to bind to uridine (Fig. 1.8) (Hartmann et al., 2014;
Van Nguyen et al., 2016). Studying a drug that is known to work through CRBN
could serve as a model system to engineering newer, more potent, andmore selective
drugs.
1.5 Immunomodulatory Drugs as a Model System to Inform the Design of
Proteolysis Targeting Chimeras
CRBN is a substrate receptor that has previously shown a lot of promise for redi-
recting to catalyze the degradation of a therapeutic target, because it has a well
defined hydrophobic binding pocket that enables precise placement of a therapeutic
target adjacent to the ubiquitinated E2. Therefore, understanding how a drug that is
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Figure 1.7: CRBN is comprised of an N terminal Lon protease like domain, a C
terminal pseudouridine like domain, and a seven α helical domain. The seven α
helical domain forms the interface with DDB1, the adapter to the Cullin, between
the two WD40 domains.
Figure 1.8: CRBN has a binding pocket that is flanked by three tryptophans. This
binding pocket is in the methionine sulfoxide reductase-like domain, and is normally
used to recognize acetyl lysine and uridine.
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known to work through redirecting what proteins CRBN recognizes would act as a
model system to facilitate the understanding of how drugs in this entire class might
work. Thalidomide was previously demonstrated to be a drug that was effective
towards redirecting CRBN to target novel proteins for degradation (Lu et al., 2014).
Thalidomide was originally prescribed as a sedative to treat morning sickness, and
was rapidly cleared for usage in humans because of its low toxicity in mice. How-
ever, children born to the women who took the drug had horrific birth defects, as
their limbs did not form properly. As a result of the public outcry, the drug was
abruptly withdrawn from the market.
Years later, thalidomide was approved for limited usage because it was found to
be effective towards treating a specific side effect of leprosy, erythema nodosum
leprosum. Erythema nodosum leprosum is a complication from leprosy that is
caused by massive inflammation from overproduction of a specific cytokine, the
first evidence that indicated that thalidomide would be effective towards regulating
the immune response (Sheskin, 1965). In the late 1990s, it was serendipitously
discovered that thalidomidewas effective towards the treatment ofmultiplemyeloma
(Palumbo et al., 2008). Multiple myeloma is a cancer of the plasma cells, which
are normally produced in the bone marrow and produce antibodies to fight off
infection. However, during multiple myeloma, one clone hyperproliferates and
produces defective versions of antibodies.
Therefore, one of the primary ways that multiple myeloma is diagnosed is through
the increased viscosity of the blood from hyperproduction of antibodies (up to
30g/L) (Kopp, Beirne, and Burns, 1967). Treatment of patients with thalidomide
decreases the production of aberrant antibodies, indicating that this drug is effective
towards multiple myeloma. Subsequently, two different analogs, lenalidomide and
pomalidomide, were shown to be significantly more potent and were approved as
therapies (Bartlett, Dredge, and Dalgleish, 2004). Collectively, thalidomide and
its analogs are referred to as IMiDs, short for immunomodulatory drugs, for their
ability to adjust the immune system’s response. However, the identity of the primary
target of IMiDs was still unknown.
Within five years of approving thalidomide for the treatment of multiple myeloma by
the FDA, CRBNwas identified as its primary binding partner. In these experiments,
Handa and coworkers devised a resin with thalidomide immobilized onto it to
capture any interacting partners, and identify the binding partners with shotgun
mass spectrometry (Takumi Ito et al., 2010). Thalidomide is a heterobifunctional
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molecule with a glutarimide moiety that was shown to bind to the hydrophobic
binding pocket of CRBN, and a phthalimide moiety (AEA Lopez-Girona et al.,
2012). However, initially it was unknown if thalidomide primarily worked to block
the degradation of endogenous substrates, or if it worked by recruiting novel proteins
for degradation via the phthalimide moiety. Comparing the effect of thalidomide
treatment in utero to the phenotype of the knock out animal could distinguish
between the two possible outcomes.
In humans, truncating the C terminal domain of CRBN, widely believed to be the
substrate binding domain, was shown to result in amildmental retardation phenotype
(Higgins et al., 2004). In mice, ablation of CRBN resulted in a pseudo starvation
phenotype (K.M. Lee et al., 2013). Since in both of these cases, animals with CRBN
knocked out or where the E3 ligase activity was inhibitedwere formedwith complete
limbs, it would stand to reason that the primary teratogenic effect of the drug was
not through inhibition. Additionally, ablation of CRBN resulted in resistance to
lenalidomide, indicating that the drug could not work through inhibition of CRBN
(Zhu et al., 2011). One alternative strategy is to look at how addition of thalidomide
or thalidomide analogs influence degradation of specific endogenous substrates.
Additional work identified MEIS2 as an endogenous substrate, binding of which
was shown to be blocked by addition of IMiDs (Fischer et al., 2014). Therefore, it
appears thalidomide can act as both an inhibitor and to recruit novel proteins, which
needs to be determined on a case by case basis, showing the importance of being
able to identify specific substrates.
Thalidomide is made up of two portions: a glutarimide moiety that was previously
shown to be necessary for binding to CRBN, and a phthalimide moiety. The
phthalimide part of the thalidomide was shown to mediate interactions with de novo
substrate, specifically recruiting proteins with a βhairpin loop. Proteins with this
motif, like proteins with a C2H2 zinc finger motif (α helix and βhairpin, with two
cysteines and 2 histidine coordinating a zinc), aswell as CaseinKinase 1α, have been
shown to interact with this protein (Petzold, Fischer, and Thomä, 2016). Critically,
many of the proteins that were identified to be recruited, like Ikaros, were proteins
that were previously believed to be undruggable because of the lack of a well-defined
binding site (Lu et al., 2014). Therefore, thalidomide works by recruiting a number
of different proteins for degradation. Recent work pinpointed a transcription factor,
SALL4, as the protein responsible for the teratogenic effects (Donovan et al., 2018).
Additional analogs like lenalidomide and pomalidomide have been shown to be
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significantly more potent and more selective, and primarily are modified at the
phthalimide ring. Understanding the identity of specific substrates and how varying
the substitution along the ring changes the identity of the substrates that are recruited
for degradation would provide the information to inform the development of more
potent and more selective analogs.
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C h a p t e r 2
SUBUNIT SELECTIVE DEGRADATION OF WIZ, A NOVEL
SUBSTRATE OF LENALIDOMIDE AND POMALIDOMIDE
2.1 Abstract
Immunomodulators (IMiDs) are an effective class of drugs used to treat blood
cancers. IMiDs are believed to work by recruiting protein targets containing a
-hairpin motif for ubiquitination by E3 ubiquitin ligase complexes composed of
cereblon (CRBN), Cullin-4a (CUL4a), DNA Damage Binding protein-1 (DDB1),
and Ring Box-1 (RBX1). The ubiquitinated protein is subsequently degraded by
the proteasome. By characterizing the repertoire of proteins that show an increased
physical association with CRBN after IMiD treatment, we identified a novel IMiD
substrate, Widely Interspaced Zinc Finger Motifs (WIZ). WIZ contains a C2H2
zinc finger domain, like several other substrates that were previously character-
ized. We demonstrate that IMiDs with amine at the 4’ position of the phthalimide
ring (lenalidomide and pomalidomide) stabilize physical association of WIZ with
CRBN, deplete WIZ steady state protein levels in a way that is dependent on E3
ligase activity, and enhance the rate of degradation. These findings illustrate the
importance of systematically characterizing the full repertoire of proteins that are
targeted for degradation by IMiD compounds, to better understand the mechanisms
and consequences of IMiD-induced protein degradation.
2.2 Introduction
Redirecting the existing cellular degradationmachinery to remove unwanted compo-
nents rapidly and specifically is potentially a versatile therapeutic approach (Cromm
and Crews, 2017). One possible strategy to achieve this goal is to redirect the pro-
teasome, a large enzyme that digests proteins. Selective elimination of one subunit
of a multi-protein complex by this approach is possible because the proteasome
can extract a single subunit from a complex, unfold it, and thread it into its inner
chamber, where the protease active sites reside (Finley, 2009). Therefore, what is
needed is a strategy to redirect the proteasome to remove a therapeutic target in
addition to its endogenous substrates.
The proteasome normally identifies and enriches for proteins that need to be remove
by using ubiquitin as an affinity tag (Hershko and Heller, 1985; Pickart and Eddins,
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2004). Ubiquitin is an 8 kDa protein that is ubiquitously expressed in eukaryotic
organisms (Goldstein et al., 1975). TheC-terminal glycine on ubiquitin is conjugated
to the amine on lysines of the target proteins via an isopeptide linkage. Formation
of a ubiquitin polymer with at least 4 monomeric units yields a signal that binds
tightly to the proteasome (Thrower et al., 2000; Wickliffe et al., 2011). Therefore,
to degrade a therapeutic target, a drug would need to catalyze the ubiquitination of
the target to redirect it to the proteasome.
Three enzymes act in tandem to catalyze selective ubiquitination of proteins (Her-
shko and Heller, 1985; Jentsch, 1992; Hochstrasser and Varshavsky, 1990). E1 first
converts the C-terminal carboxylic acid on ubiquitin into a more reactive thioester to
enhance the rate of reaction, as the C-terminus of ubiquitin is fairly chemically inert.
The activated ubiquitin is transferred as a thioester to an E2, and the E2 ubiquitin
thioester then binds to an E3 enzyme, which also binds to substrate. RING-type E3
enzymes position the E2 for subsequent transfer of ubiquitin to a lysine residue on
the bound substrate (Petroski and R. J. Deshaies, 2005). Since E3 ubiquitin ligases
are the components of this pathway that identify which proteins get ubiquitinated,
one strategy to redirect the proteasome to digest a therapeutic target is to modify the
substrate specificity of an E3 ubiquitin ligase to recognize the protein of interest.
One class of E3 ubiquitin ligases that have been successfully redirected towards
a therapeutic target (i.e. neosubstrate) are cullin-RING type E3 ubiquitin ligases
(CRLs) (Angers et al., 2006; Sakamoto, Kim, Kumagai, et al., 2001; Winter et
al., 2015; J. Lu et al., 2015; Sakamoto, Kim, Verma, et al., 2003; Schneekloth
et al., 2004; Gandhi et al., 2014; Uehara et al., 2017; Han et al., 2017; Bondeson
et al., 2015). A distinguishing feature of CRLs is that they contain interchangeable
subunits that recruits specific substrates to the enzymatic core (Petroski and R. J.
Deshaies, 2005). CRLs work by catalyzing the discharge of ubiquitin from E2 onto
a lysine residue of a juxtaposed natural or neosubstrate.
Investigating molecules that work by re-directing CRL activity toward neosubstrates
can inform the design of future drugs. One class of drugs that redirect CRL
activity towards neosubstrates is referred to as IMiDs, or immunomodulatory drugs
(Singhal et al., 1999). IMiDs have been shown to be effective for the treatment of
hematological malignancies by redirecting cereblon (CRBN), the interchangeable
substrate receptor that determines the specificity of theCRL4CRBN complex to recruit
a set of neosubstrates (Fig. 2.1a) (Gandhi et al., 2014; G. Lu et al., 2014; Krönke,
Fink, et al., 2015; Krönke, Udeshi, et al., 2014). CRBN is one of many substrate
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Figure 2.1: Mechanism of action for IMiDs. (a) CRBN is normally in complex
with DDB1, which in turn interacts with CUL4-RBX1 to form the ubiquitin ligase
CRL4CRBN. IMiDs nucleate a novel protein-protein interaction between CRBN and
a cellular protein (neo-substrate). Ubiquitin-thioesterified to a ubiquitin conjugating
enzyme (E2) is recruited to the CRL4CRBN by RBX1, priming both for bringing ac-
tivated ubiquitin into proximity of the neosubstrate. (b) General structure of IMiDs.
Addition of the blue NH2 group to thalidomide yields lenalidomide. Removal of
the red carbonyl group from lenalidomide yields pomalidomide.
receptors that are recruited to CUL4-RBX1 by DDB1 to form CRL4 complexes
(Fig. 2.1a) (Angers et al., 2006; Ito et al., 2010).
IMiDs are bipartite molecules that act as a molecular bridge to link neosubstrates to
CRBN. The glutarimide moiety binds CRBN, and the pthalimide moiety binds to
protein targets (Fig. 2.1b) (Chamberlain et al., 2014; Fischer et al., 2014). All known
IMiD-dependent neosubstrates reported for CRL4CRBN are predicted to contain a
β-hairpin motif like Casein Kinase 1α (CK1α) and C2H2 zinc finger proteins Ikaros
(IKZF1), Aiolos (IKZF3), E3 ubiquitin-protein ligase ZFP91 (ZFP91), Sal-like
protein 4 (SALL4) and Aiolos (IKZF3) (Fig. 2.1a) (Gandhi et al., 2014; G. Lu et al.,
2014; Krönke, Fink, et al., 2015; Krönke, Udeshi, et al., 2014; Donovan et al., 2018;
An et al., 2017). Crystal structures have shown that β-hairpin motif comes into
contact with the pthalimide moiety of IMiDs, which explains how these drugs work
(Petzold, Fischer, and Thomä, 2016; Matyskiela et al., 2016).
Because novel substrates are recruited to CRBN through the pthalimide moiety
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of IMiDs, understanding how modification of the basic bicyclic IMiD scaffold
influences the identity of the neosubstrates that are recruited to CRBN will be
critical towards the development of new analogs with different patterns of selectivity
(Fig. 2.1b). Interestingly, relatively modest alterations to the IMiD scaffold can
have surprisingly dramatic effects. For example, substitution of an amine at the 4’
position of thalidomide (Fig. 2.1b) (as occurs in lenalidomide and pomalidomide)
results in a 100 to 1,000-fold increase in potency (Muller et al., 1999). Another
dramatic example of specificity is seen with deletion of a simple carbonyl from
pomalidomide to generate lenalidomide (Fig. 2.1b), which enables targeting of
the neosubstrate CK1α for ubiquitination and degradation (Krönke, Fink, et al.,
2015; Petzold, Fischer, and Thomä, 2016). Thus, relatively subtle modifications to
the IMiD chemical scaffold result in dramatic changes in its biological properties.
Additionally, it remains unknown how the effects of IMiDs are modified in different
cell types. If we are to understand how to harness targeted protein degradation,
it will be important to understand the physical and chemical basis for targeting by
identifying and characterizing specific neosubstrates.
IMiDs enhance physical association of CRBN with proteins with Zinc Finger
domains
Previous IMiD substrates have been identified in proteomics experiments by deter-
mining which protein accumulate as ubiquitinated intermediates or exhibit a shorter
half life in the presence of IMiDs (G. Lu et al., 2014; An et al., 2017; Krönke, Udeshi,
et al., 2014; Donovan et al., 2018; Krönke, Fink, et al., 2015). However, there are
several disadvantages to both of these methods. First, ubiquitinated intermediates
typically account for a tiny fraction of the total protein, and only a tiny fraction of
all peptides from a protein have ubiquitin conjugated to them (R. Deshaies, 1999).
Second, the rate of decay is nonlinear, and the half-life of proteins can range from
minutes to months, potentially confounding a large-scale screen analyzed at a single
time point (Toyama et al., 2013). To circumvent these issues, we chose to identify
proteins whose physical association with CRBN was enhanced upon treatment with
IMiD, as we reasoned that this was the most direct and sensitive method. To ac-
complish this, we used a THP-1 cell line that was transiently transfected to express
FLAG-CRBN (Fig. 2.2a).
We identified candidate proteins by treating cells with or without lenalidomide
for 2 hours, immunoprecipitating for CRBN via the FLAG epitope, and identifying
which proteins showed enhanced physical association with CRBN in the presence of
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Figure 2.2: Proteins with Zinc Finger Domains show enhanced IMiD dependent
enhanced physical association with CRBN. (a) Outline of IP-MS strategy to identify
proteins that show an enhanced physical association. (b) Peptide count of proteins
identified in the experiment. This includes those known to bind CRBN, known
core components of the CRL4CRBN complex, zinc finger proteins, and novel binding
partners.
lenalidomide via quantitative shotgun mass spectrometry (Fig. 2.2a). Components
of the enzymatic core of CRL4CRBN (CUL4a and RBX1) and the adapter (DDB1)
that scaffolds CRBN’s interaction with the enzymatic core were recovered in equal
amounts regardless of the presence or absence of lenalidomide (Fig. 2.2b).
Previously characterized neosubstrates (ZFP91, IKZF1, IKZF3, CK1α) showed
IMiD-dependent association, validating this approach (Fig. 2.2b) (Gandhi et al.,
2014; An et al., 2017; Krönke, Fink, et al., 2015; G. Lu et al., 2014; Krönke, Udeshi,
et al., 2014). However, one limitation of this approach is that enhanced physical
association with CRBN might not necessarily result in a productive degradation
event (Eichner et al., 2016).
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Figure 2.3: WIZ protein abundance shows IMiD dependent regulation. L363 cells
were maintained in RPMI-1640 with 10% FBS and 2 μMglutamine before treatment
with (a) pomalidomide, (b) lenalidomide, or (c) thalidomide for 12 hours at 0, 1 or 10
μM. Cell lysates were processed for immunoblotting and he signals were quantified
on a LICOR odyssey. The median level of each protein normalized to no drug and
the GAPDH signal in the same samples is shown below the immunoblot image for
each set of triplicates. All protein levels were normalized to GAPDH, which served
as a loading control. The previously identified substrates ZFP91, IKZF1, and CK1α
serve as positive controls. PATZ1, ZFP684, and ZNF644 are the other zinc finger
proteins screened.
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Figure 2.4: IMiD regulation is cell type specificity. THP-1 Cells were then treated
with (a) pomalidomide or (b) lenalidomide 0, 1, or 10 µM. for 12, 24, 36, and
48 hours. Cell lysates were separated by SDS PAGE, and immunoblotted against
antibodies for WIZ, CRBN, IKZF1, CK1α, and GAPDH.
2.3 IMiD regulation shows cell type dependence
To understand how generalizable IMiD-dependent depletion of WIZ was across
different cell types, THP-1 cells were treated with IMiDs (0, 1, and 10 μM) with
a 4’ amine modification for 12, 24, 36, and 48 hours (Fig. 2.4a–b). Previously
characterized IMiD dependent substrates like IKZF1 (G. Lu et al., 2014; Krönke,
Udeshi, et al., 2014; Gandhi et al., 2014) were also immunoblotted as a positive
control. Unlike what we observed in L363 cells (Fig. 2.3a), no reduction of WIZ
was observed in THP-1 cells (Fig. 2.4a-b), indicating that the IMiD effect shows
cell type dependence. Previous work had indicated that WIZ was downregulated in
H9 hESC (Donovan et al., 2018). Thus, the IMiD effect on WIZ shows cell type
dependence.
WIZ binding partners are not regulated by IMiD
WIZ is a protein that is normally in a transcriptional complexwith EHMT1, EHMT2,
and ZNF644 (Bian, Chen, and Yu, 2015; Ueda et al., 2006). It is believed to target
methyltransferases to specificDNAsequences via its zinc fingermotif. To investigate
out how many of the IMiD-dependent binding events translated into productive
degradation, we examined by immunoblotting a subset of the identified proteins to
see if their steady state levels dropped after IMiD treatment(Fig. 2.3a–c). We selected
proteins with a zinc finger domain, because some previously characterized IMiD-
dependent substrates (e.g. IKZF1, Aiolos, ZFP91, ZFP692) are zinc finger proteins
(Gandhi et al., 2014; An et al., 2017; Krönke, Udeshi, et al., 2014; G. Lu et al.,
2014; Krönke, Fink, et al., 2015; Donovan et al., 2018). L363 cells were treated with
pomalidomide, lenalidomide, or thalidomide for 12 hours at multiple doses (0, 1, and
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Figure 2.5: IMiDs regulate the abundance of WIZ, but not the other components of
the complex EHMT1, EHMT2, and ZNF644. MM.1s cells were treated in triplicate
for 24 hours with (a) pomalidomide or (b) lenalidomide at 0, 1, or 10 μM.Cell lysates
were separated by SDS PAGE, and immunoblotted against antibodies against Wiz,
EHMT1, EHMT2, and ZNF644.
10 μM), in biological triplicate (Fig. 2.3a–c). Both isoforms of WIZ (the identity of
the isoforms was confirmed by knockdown) (Fig. 2.6) showed the largest fold change
after treatment with pomalidomide (Fig. 2.3a). Previously characterized substrates
(IKZF1) showed IMiD dependent depletion (Fig. 2.3a–c). Additionally, substrates
such as CK1α that were known to be specific to lenalidomide, showed lenalidomide
dependent depletion, (Fig. 2.3b) as had been reported previously (Krönke, Fink,
et al., 2015).
Figure 2.6: THP-1 cells were transiently transfected with an siRNA against WIZ,
EHMT1, EHMT2, or ZNF644. Cells were harvested after 48 or 72 hours and
immmunoblotted against different commercially available antibodies.
The reduction in WIZ increased over time and showed a larger effect after treatment
pomalidomide than lenalidomide (Fig. 2.3a–c). WIZ is a protein that is normally
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in a transcriptional complex with EHMT1, EHMT2, and ZNF644 (Bian, Chen, and
Yu, 2015). It is believed to target methyltransferases to specific DNA sequences via
its zinc finger motif. Our mass spec data revealed the entire complex was recruited to
CRBN after treatment with IMiD (Fig. 2.2b). However, immunoblotting indicated
that WIZ was the only component of this complex that was depleted (Fig. 2.5a,b).
WIZ binding partners are not regulated by IMiD
WIZ is a protein that is normally ina transcriptional complexwith EHMT1, EHMT2,
and ZNF644 (Bian, Chen, and Yu, 2015; Ueda et al., 2006) It is believed to target
methyltransferases to specific DNA sequences via its zinc finger motif. Our mass
spec data revealed the entire complex was recruited to CRBN after treatment with
IMiD (Fig. 2.1b). To tease out if WIZ was the only component of the transcriptional
complex that showed regulation, MM.1s cells were treated with lenalidomide or
pomalidomide (0, 1 or 10 μM) for 24 hours and WIZ and EHMT1, EHMT2, and
ZNF644 were evaluated by immunoblotting (Fig. 2.5a–c). Depletion of both WIZ
and the validated substrate IKZF1 were observed, but the other components of the
WIZ transcriptional complex remained stable.
Levels of WIZ are specifically modulated by IMiDs with an amine modification
at the 4’ position
To elucidate how subtle modifications in the IMiD scaffold influenced WIZ deple-
tion, MM.1S cells were treated with pomalidomide, lenalidomide, or thalidomide
(0, 1, and 10 μM) at 12 , 24, 36, and 48 hours (Fig. 2.7a–c). Both isoforms of WIZ
showed the largest fold change upon treatment with IMiDs with an amine in the 4’
position (lenalidomide and pomalidomide)(Fig. 2.7a–b).
IMiD dependent depletion of WIZ is dependent on CRBN’s E3 ubiquitin ligase
activity
IMiDs enhanced the physical association between WIZ and CRBN, resulting in
the depletion of WIZ which is consistent with the hypothesis that WIZ is a new
CRL4CRBN neosubstrate.
We next sought to directly test this hypothesis. Depletion of CRBN in MM.1s cells
strongly blocked pomalidomide-induced depletion ofWIZ (Fig. 2.7b, d), confirming
that CRBNwas indeed required for the effect. To address the role of CRL E3 activity
and the proteasome, L363 cells were treated with 0, 1, or 10 µMof pomalidomide for
12 hours in the absence or presence of the Nedd8 conjugation inhibitor pevonedistat
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Figure 2.7: Wiz protein abundance is specific to IMiDs modified with an amine at
the 4’ position. (a-c) MM.1s or (d) MM.1s cells with CRBN knocked down with an
shRNAwere treated with (a) lenalidomide, (b) (d) pomalidomide, or (c) thalidomide
at 0, 1, or 10 µM for 12- 48 hours. Cell lysates were separated by SDS PAGE, and
immunoblotted against antibodies for WIZ, CRBN, IKZF1, CK1α, and GAPDH.
or the proteasome inhibitor bortezomib (Fig. 2.8a-c) (Adams et al., 1999; Soucy et
al., 2009). IMiD depletion ofWIZ and known substrates such as IKZF1was blocked
upon cotreatment with proteasome inhibitor, indicating the effect was dependent on
proteasome activity (Fig. 2.8a,b).
Nedd8 is a ubiquitin-like protein that activates CRLs upon its conjugation to the
cullin subunit (R. J. Deshaies, Emberley, and Saha, 2010). Co-treatment with
250 nM pevondistat showed accumulation of CUL4 in the de-neddylated version,
indicating that the enzymatic core of the complex would be catalytically inactive
(Fig. 2.8a, c). IMiD depletion of WIZ and known substrates such as IKZF1 was
also blocked upon cotreatment with pevondistat, indicating IMiD induced depletion
was dependent upon the core complex being enzymatically active (Fig. 2.8a,c).
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Figure 2.8: IMiD induced degradation of WIZ is dependent on E3 ubiquitin ligase
activity and proteasome degradation. L363 cells weremaintained inRPMIwith 10%
FBS before treatment with pomalidomide at 0, 1, or 10 μM in biological triplicate.
They were cotreated with either (a) DMSO, (b) a proteasome inhibitor bortezomib
, or (c) a Nedd-8 conjugation inhibitor pevodnestat. Cell lysates were separated by
SDS-page and immunoblotted against the indicated antibodies. NRF1 was used as
a positive control, for the proteasome inhibitor. IKZF1 was a positive control for
IMiD treatment. GAPDH was the loading control. The action of pevondistat was
confirmed by its effect on CUL4 neddylation.
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IMiD dependent depletion of WIZ protein levels was due to catalyzing the rate
of decay
Although we found IMiD dependent depletion of WIZ was dependent on both
CRBN and CRL ubiquitin ligase activity (Fig. 2.7d) (Fig. 2.8a–c), it could be due
to increased degradation of WIZ or inhibition of WIZ expression. To decouple
these two possible outcomes, we compared the rate of decay by treating cells with
or without IMiD in the presence of an inhibitor of translation (Fig. 2.8a-c) (Obrig
et al., 1971). We saw that both isoforms of WIZ, as well as IKZF1, a known IMiD
substrate, experienced a higher rate of decay upon addition of IMiD (Fig. 2.8b,c),
consistent with this being due to an increased rate of degradation (G. Lu et al., 2014;
Krönke, Udeshi, et al., 2014).
Figure 2.9: Pomalidomide stimulates the degradation of WIZ. MM.1s cells were
maintained in RPMI 1640 before treatment with cycloheximide (150 μM/mL) with
or without 10 μM of pomalidomide. Cells were harvested at 0, 2, 4, 6, 8, 12, and 14
hours before being separated by SDS-PAGE and immunoblotted for Wiz, IKZF1,
and GAPDH.
Discussion
Targeted protein degradation is rapidly becoming an area of intense interest for the
biopharmaceutical industry (Crews, 2010). The overall goal for researchers in this
area is to design a drug that selectively targets a particular protein of interest for
ubiquitin-dependent degradation via the proteasome. One particular class of drugs,
the IMiDs, achieves its effects through selective destruction of specific neosubstrates
via the CRL4CRBN ubiquitin ligase pathway (Ito et al., 2010; G. Lu et al., 2014;
Krönke, Udeshi, et al., 2014). Interestingly, different IMiDs that differ from each
other in subtle ways elicit the degradation of different sets of overlapping neosub-
strates. To better understand the biological effects of IMiDs and to gain insight
into the mechanisms by which IMiDs recruit substrates to CRBN, we employed
an affinity purification-mass spectrometry approach to identify proteins that bound
CRBN in an IMiD-dependent manner (Fig. 2.2a,b). This led to the identification
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of a dozen proteins, including the previously-described CRL4CRBN neosubstrates
IKZF1, IKZF3, ZFP91, ZNF692 and CK1α (Fig. 2.2a,b)(Krönke, Fink, et al., 2015;
Krönke, Udeshi, et al., 2014; G. Lu et al., 2014; An et al., 2017; Sievers et al., 2018).
In addition, we identified a number of zinc finger proteins, includingWIZ. Note that
while this work was being being prepared for submission, Thoma and colleagues
reported the interaction of a large collection of zinc fingers with CRBN, including
those reported here (Sievers et al., 2018).
We show here that WIZ is a bonda-fide neosubstrate for CRL4CRBN (Fig. 2.7a,d). In
addition to increasing association ofWIZwith CRBN, IMiDs also induced depletion
of WIZ that was dependent on the CRBN protein, CRL activity (as determined
with the pan-CRL inhibitor pevonedistat), and proteasome activity (Fig. 2.9a–c).
Importantly, depletion of WIZ was due to an increase in its rate of degradation
(Fig. 2.9a,b). The effect of IMiDs on WIZ degradation was selective, in that only
IMiDs with an amino group at the 4’ position (lenalidomide and pomalidomide)
induced degradation (Fig. 2.7a,b). This is consistent with prior observations that
subtle structural differences in IMiD structure can have powerful discriminating
effects on substrates such as CK1α (Krönke, Udeshi, et al., 2014; Krönke, Fink,
et al., 2015). In addition, we observed IMiD-dependent depletion of WIZ in L363
but not in THP-1 cells. We do not know the reason for this selectivity. However, it
is not due to the inability of WIZ to bind transfected CRBN in an IMiD-dependent
manner in these cells(Fig. 2.2b). This selectivity points to the potential to develop
therapeutic agents that induce degradation of target proteins in a cell type specific
manner.
Our data, combinedwith other recently reported results, raise the question ofwhether
the effects of IMiDs in vivo are more complex than originally envisioned, and could
potentially be influenced by depletion of multiple proteins in addition to the original
neosubstrates IKZF1 and IKZF3 (Sievers et al., 2018).
A great deal of effort is being invested in developing proteolysis-targeting chimeric
molecules (PROTACs) that, like IMiDs, induce the degradation of specific proteins
to achieve a therapeutic effect (R. J. Deshaies, 2015). A result we observed here that
is of particular relevance to those efforts is that IMiD induced depletion is highly
selective for a single subunit for a multisubunit complex. WIZ associates with
EHMT1, EHMT2, and ZNF644 to form a gene regulatory complex, and all four of
these proteins were recruited to CRBN in the presence of IMiD (Fig. 2.2a,b) (An
et al., 2017; Ueda et al., 2006). However, onlyWIZwas degraded. This is consistent
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with the previously observed subunit selectivity of the ubiquitin proteasome pathway
both in vivo and in reconstituted systems (Verma et al., 2001; Johnson, Gonda,
and Varshavsky, 1990). Harnessing the power of subunit-selective degradation to
remodel cellular machines to achieve a highly selective therapeutic outcome holds
promise for the development of a suite of next-generation therapeutics.
Experimental Procedures
Materials
Bortezomib (B-1408) was purchased fromLCLaboratories. Pomalidomide (P0018-
25MG) and N-ethyl maleimide (E3876-5G) were purchased from Sigma Aldrich.
Lenalidomide (HY-A0003) and pevonedistat (905579-51-3) were purchased from
MedChem Express. All were prepared as single-use DMSO stocks, and stored at
-20o C before usage. Laemmli Buffer (1610737) was purchased from Biorad. BSA
(9998S) was purchased from Cell Signaling Technology.
Antibodies
GAPDH (SC-365062) antibody was from Santa Cruz Biotechnology. CUL4a
(2699S), DDB1 (A300-462A), EHMT1 (A301-642A-M), and ZNF644 (A301-
642a-M) antibodies were from Bethyl Laboratories. CRBN (HPA045910) and
FLAG (F1804) antibodies, were from Sigma Aldrich. WIZ (ab92334), ZNF521
(ab156271), CK1α (ab108296), and EHMT1 (ab185050) antibodies were from
Abcam. PATZ1 (PA5-30478), ZNF684 (PA5-40984), and ZFP91 (PA5-43064) an-
tibodies were from Thermo Fischer Scientific. Anti-Rabbit IgG IR800 (926-32211)
was purchased from Li-COR Biosciences. Anti-Mouse IgG IR680 (A10038) was
purchased from Invitrogen.
Cell lines
MM.1s and THP-1 cells were purchased from ATCC. L363 cells were provided by
Francesco Parlati, Calithera Biosciences, South San Francisco. Cells were grown
in RPMI-1640 (ATCC formulation), with 10% heat-inactivated fetal bovine serum
(FBS), 2 μM glutamine, and penicillin-steptomycin. THP-1 cells were supple-
mented with 50 μM β-mercaptoethanol. Cell lines were tested for mycoplasma
using Lonza’s MycoAlert Mycoplasma Detection kit and authenticated by Laragen
using PowerPlex 16 system, as well as the Cell Line ID.
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Western blot analysis
MM.1s cell for each sample, as well as a replicate to measure protein levels were
harvested by centrifugation and resuspended in pre-warmedRPMI16–40 at 1million
cells/mL. They were then seeded onto 24 well plates, for 1.5 mL total volume.
Pomalidomide was added from a 1000x stock. Cells were spun down, and the
medium was aspirated, and flash frozen for processing later. A separate replicate to
normalize protein concentration was rinsed with PBS 2x, before being flash frozen.
Samples were then solubilized in 200 μL of Laemmle buffer supplemented with
fresh β-mercaptoethanol and protease inhibitor cocktail. Cell lysates were sonicated
(5 s; 10%) and cleared by centrifugation before boiling for 3 minutes. Boiled lysates
were cleared by centrifugation (14,000 xg). Relative concentrations were calculated
based on the BCA assays, and the total lysate volume was adjusted according to that.
Samples were loaded onto 4–12% protein gels and transferred for 3 hours at 70 V,
with stirring.
RNAi-Mediated knockdown
siRNAs were purchased from Santa Cruz Biotechnology. Cells were seeded at a
final concentration of 500,000/mL (THP-1 cells), and transfected with Opti-MEM
and Lipofectamine RNAimax, as previously described. Cells were harvested after
48, and 72 hours, and analyzed for efficiency of knockdown.
Cycloheximide Chase
MM.1s cells were seeded at 106 cells/mL in complete RPMI 1640 with 10% FBS in
24 well plates. Cells were treated with 0 or 10 μM pomalidomide, along with 150
μg/mL of cycloheximide to initiate the chase. Cells were harvested at the indicated
time, and subjected to immunoblot analysis.
Immunoprecipitation
THP-1 cells were transiently transfected with a plasmid expressing FLAG CRBN.
After 36 hours, cells were treated with lenalidomide for 2 hours (1 μM). Cells were
lysed in 50 mM HEPES, pH 7.5, 70 mM KOAc, 5 mMMg(OAc)2, 0.2% n-dodecyl-
β-D-maltoside with protease inhibitor for 30 minutes at 4 °C. Lysates were pelleted
for 15 minutes at 16,000 g to remove cellular debris. Supernatent was incubated
with anti-FLAGM2 affinity gel for 2 hr at 4 °C. The anti-FLAGM2 affinity gel was
washed with lysis buffer 3 times, then with 100 mM Tris-HCL (pH 8.5) two times.
Samples were eluted with 100 mM Tris-HCl (pH 8.5) with 10M urea.
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Mass Spectrometric analysis
Eluted sampleswere spikedwith 4.48mMDTT (1/278) to reach a final concentration
of 1.25 M DTT, to be reduced. Reduced samples were alkylated with 10 mM NEM
for 30 min at room temperature in the dark. Reduced and alkylated samples were
digested with Lys-C (Wako) at a 1:200 ratio for 4 hr at RT. Partially digested
lysates spiked with 1 mM CaCl2 were diluted with 50 mM Tris (pH 8.0) down to
2 M urea before being digested with sequence grade trypsin (Promega) at 1:100
37°C overnight in the dark. The reaction was quenched after 15 hr by adding
trifluoroacetic acid (TFA) to 0.1%. Lysates were cleared via centrifugation at
4000xg for 15 minutes. Peptides were were desalted using a 500 mg capacity
Sep-pak column that initially was hydrated using 7 column volumes of ACN (21
ml), followed by an equilibration step with 7 column volumes of Buffer A (0.1%
TFA in H2O) (21 ml). Cleared peptides were loaded onto the resin by gravity flow,
washed with 7 column volumes of Buffer A, followed by 3 column volumes of
Wash buffer (0.1% TFA, 5% ACN in H2O). Desalted peptides were eluted using
2 column volumes of Elution buffer (0.1% TFA, 40% ACN in H2O) (6 ml). The
resulting peptide sample was frozen by storing at 80°C for at least 1 hr and dried via
lyphilization.
NanoLC-MS/MS analysis
The dried immunoprecipitated peptides were resuspend in Buffer A (0.2% Formic
Acid, 2% ACN, nanoLC grade 97.8% H2O) and subjected to proteomic analysis
using an EASY II nano-UPLC (Thermo Fisher Scientific) connected on-line to an
Orbitrap Elite hybridmass spectrometer with a nanoelectrospray ion source (Thermo
Scientific) using settings similar to those previously described (Porras-Yakushi and
Hess, 2014). Peptides were separated using a 15 cm silica analytical column with
a 75 µm inner diameter packed in-house with reversed phase ReproSil-Pur C18AQ
3 µm resin (Dr Maisch GmbH, Amerbuch-Entringen, Germany). The flow rate was
set to 350 nl/min, using a linear gradient of 2%-32% B (0.2% Formic Acid, 80%
ACN, 19.8% nanoLC grade H2O). Mass spectrometry detectable samples were
analyzed on a 159 min gradient, while basic reversed phase immunoprecipitated
samples were analyzed on a 90 min gradient. The mass spectrometer was set to
collect data in a data-dependent mode, switching automatically between full-scan
MS and tandem MS acquisition. All samples were analyzed by ETD and decision
tree fragmentation. For ETD fragmentation, the fifteen most intense precursor ions
were selected, while the 20 most intense ions were selected for fragmentation using
41
the decision tree method. Data acquisition was managed using Xcalibur 2.0.7 and
Tune 2.4 software (Thermo Fisher Scientific).
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Data Analysis
Raw data was searched using MaxQuant (Jürgen Cox and Mann, 2008; Jurgen
Cox et al., 2011), version 1.6.5.0. Precursor mass tolerance was set to 4.5 ppm
after recalibration and fragment tolerance was 0.5 Da. Oxidation of methionine
and protein N-terminal acetylation were specified as variable modifications and
carbamidomethylation of cysteine was specified as a fixed modification. Trypsin
was specified as the digestion enzyme, with up to two missed cleavages allowed.
Spectra were searched against the UniProt human database (93591 entries) and
a contaminant database (246 entries). Score thresholds were established so that
peptide and protein false discovery rates were less than 1% as estimated by a target-
decoy approach. Match between runs and iBAQ quantitation (Schwanhäusser et al.,
2011) were enabled. iBAQ parts per million (ppm) abundances were calculated by
multiplying individual protein iBAQ abundances by 106 and dividing by the sum of
all non-contaminant protein iBAQ values
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